Background: The cytokines are potent inflammatory factors that regulate each stage of atherosclerosis leading to the disease development. Interleukin-10 (IL-10) as an anti-inflammatory cytokine can develop atherosclerosis by inhibiting the synthesis of metalloproteinase. Moreover, IL-10 promotes the plaque stability by preserving the extracellular matrix and fibrous cap. Aim: We evaluated the association of the two IL-10 promoter gene polymorphisms with susceptibility to coronary artery disease (CAD) in Iranian population. Subjects and methods: We used the Sequence Specific Primer-Polymerase Chain Reaction method to determine genotypes. We also studied mRNA expression of the IL-10 gene in Iranian CAD patients using quantitative real-time PCR.
Introduction
Growing evidence confirms the role of inflammatory responses in the pathophysiology of atherosclerotic events such as coronary artery disease (CAD). CAD develops by plaque formation and deposition in the arteries walls, causing disruption of blood flow, and is called atherosclerosis [1] . Atherosclerosis can be stimulated by multiple molecular pathways and genetic variants, which play a crucial role in the determination of susceptibility to CAD [2] . Several factors increase the risk of CAD such as age, gender, heredity, smoking, high blood cholesterol, high blood pressure, physical inactivity, and obesity. These factors make people prone to the coronary heart disease [3] . The cytokines are potent inflammatory factors that regulate each stage of atherosclerosis and leading to the development of diseases such as CAD [4] . Interleukin-10 (IL-10), as one of the most important anti-inflammatory cytokines, serves as an anti-inflammatory agent by down-regulation of the Th1 and suppression of pro-inflammatory cytokines such as IL1, IL6, IFN-c and TNF-a [5] . It also develops atherosclerosis by inhibiting the synthesis of metalloproteinase. Moreover, IL-10 promotes the stability of plaque by preserving the extracellular matrix and fibrous cap [2] . The IL-10 gene has variable sites (polymorphisms and microsatellites) which influence the level of IL-10 expression. Therefore, it may be associated directly and indirectly with the development of the CAD. In the previous study, we evaluated the association of platelet-derived growth factor b polymorphisms with CAD [6] . In this study, we investigated the 
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Subjects and methods

Study subjects
This case-control study with randomized sampling was performed to evaluate the genetic association of the two IL-10 polymorphisms [À1082G/A (rs1800870) and À819C/T (rs1800871)] with CAD. We enrolled 303 CAD patients with evidence of atherosclerosis, with known number of the vessel involved, who scheduled to undergo diagnostic coronary angiography, from March 2013 to March 2014, in Kouwsar heart center of Golestan University of Medical Sciences, Kordkuy, Iran. Inclusion criteria for patients group were the presence of a stenosis less than 50% in at least one major coronary artery. The controls group involved 343 individuals with normal coronary artery angiograms. Inclusion criteria for the control group also were the presence of normal electrocardiograms at rest, without symptoms of myocardial ischemia during exercise. In agreement with the Helsinki Declaration, all participants were aware of the study details and signed the relevant written informed consent. The Ethics Committee of Golestan University of Medical Sciences approved this study.
DNA extraction and amplification
Genomic DNA was extracted by the phenol-chloroform method following standard protocol with some modifications as described previously [7] . The IL-10(À819)C/T and (À1082)G/A polymorphisms were investigated by Sequences Specific Primerpolymerase chain reaction (SSP-PCR) using two primer sets (Table 1) . PCR reaction included 2 ll of DNA, 13 ll master mix containing 1.5 ll dNTP, 1.5 ll 10x buffer, 0.9 ll MgCl2, 2.2 ll 12% Sucrose and 0.2 unit Taq Polymerase (Qiagen, Hilden, Germany), 0.5 ll human growth hormone (hGH) primer (MWG, Ebersberg, Germany) as internal control (Table 1) , 5.2 ll dH2o and 1 ll of each specific primer (MWG, Ebersberg, Germany). The PCR reaction was performed in a Thermal Cycler (Techne, Staffordshire, UK), with the following program: 1 min at 95°C followed by 10 cycles of 15 s at 95°C, 50seconds at 62°C, 40 s at 72°C, followed by 20 cycles of 30 s at 95°C, 30seconds at 57°C and 30 s at 72°C with 5 min at 72°C as final extension. Then, PCR products were transferred on 1.5% agarose gel containing DNA safe stain and the bands were visualized on a gel documentation system (UviTec, Warwickshire, UK).
Quantitative Reverse Transcriptase PCR (RT-qPCR)
Total RNA was isolated from peripheral blood mononuclear cells (PBMCs) by the Trizol reagent (Thermo Fisher Scientific, Massachusetts, USA). In this stage, samples were selected from 80 patients and 80 normal individuals. RNA concentration was measured using a NanoDrop ND 1000 (Thermo Fisher Scientific, Massachusetts, USA). All RNA samples had a 260 nm OD equivalent to 0.4-0.9 nanograms per microliter, and a 260/280 ratio of 1.8-2.2. Total RNA was reversely transcribed to cDNA by the QuantiTect Reverse Transcriptase kit (Qiagen, Hilden, Germany). Quantitative real-time PCR was performed using a Corbett Rotor-Gene 6000 (Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions. The information of primers used to quantify IL-10 mRNA expression are shown in Table 1 . The phosphoglycerate kinase 1 (PGK1) gene was amplified as the normalized control. Real-time PCR was performed in triplicate using optimal conditions including 3 min at 95°C as a PCR initial activation step followed by two-step cycling at 95°C for3 s and 60°C for 30 s, repeated for 40 cycles. The relative expression was determined by threshold cycle (Ct) values and DDCt method as described previously [10] .
Statistical analysis
All data were analyzed by GraphPad software (version 6; San Diego, United States). Deviation from the Hardy-Weinberg assumption was checked for each polymorphism. Comparisons of the frequencies of the IL-10 alleles and genotypes between the patient and control groups were carried out using a chi-square test with Yates' correction. Data are presented as the mean ± standard deviation (SD) for parametric variables and as percentages for non-parametric values. Allele and genotype frequencies were calculated and compared between groups by non-parametric tests, and followed by Fisher's exact test. A p value of less than 0.05 was considered statistically significant.
Results
This study consisted of 646 subjects including 303 CAD patients and 343 normal subjects as the control group. The mean age of cases and controls were 59.04 ± 10.61 and 52.43 ± 10.89 years respectively. The male/female ratio was 1.50 in patients and 0.59 in controls. Deviation from the Hardy-Weinberg equation was not observed in any of the groups (v 2 < 3.84, df = 1, p < 0.05). The allele and genotype distribution of IL-10 polymorphisms in CAD patients and matched controls are shown in Table 3 . Results of this table show that there is a significant association between IL-10 (À819) T allele, and IL-10(À819) T/T genotype and CAD (p = 0.041 and p = 0.042 respectively). In addition, there is a significant asso- No significant association was observed in inheritance models of IL-10(À819) polymorphism ( Table 2 ). The haplotype analysis of IL-10(À819) and (À1082) polymorphisms showed no significant association between haplotypes and CAD ( Table 3 ). The genotype frequencies in CAD group according to a number of affected arteries are shown in Table 4 . Results of this table show that genotype T/T of IL-10(À819) polymorphism significantly associated with the two vessel disease type (p = 0.017). In addition, there is a significant association between genotype G/G of IL-10(À1082) polymorphism and the three vessel disease type (p = 0.009). The comparison of IL-10 gene expression between CAD patients and healthy controls are shown in Table 5 . The results of this table indicate that there is a significant difference in DCt values between CAD patients and control individuals (p < 0.001). As shown in Table 5 , IL-10 mRNA expression was significantly decreased 3.36-fold in samples with IL-10(À819) polymorphism and 1.98-fold in individuals with IL-10(À1082) polymorphism.
Discussion
CAD is a multifactorial and inflammatory disease that require the interaction of various risk factors such as high lipid profiles, smoking, and alcoholism [11] . IL-10 production, as an antiinflammatory cytokine that develop atherosclerosis, is controlled genetically, and as previously presented, changes in IL-10 secretion is mediated by specific IL-10 gene promoter polymorphisms [12, 13] . The analysis of genotype distribution for two IL-10 polymorphisms [(À819)C/T and (À1082)G/A] revealed that allele T in the position of À819 from start site and allele G in the position of À1082 may play an important role in increasing the susceptibility to CAD (Table 2) . Afzal et al. study reported the association analysis of three SNP polymorphisms of IL-10 gene promoter with Pakistani CAD patients at positions À592, À819 and À1082. In agreement with our results, they showed that genotypes of IL-10 (À819) T/T and IL-10(À1082) G/G are significantly associated with CAD (Table 2 ). In addition, Contrary to our results, they reported that genotype of IL-10(-1082) G/A has a negative association with CAD. A slight difference in results of two studies may be due to the type of our cases, different ethnicities, and epigenetic effects. They also analyzed the SNP haplotypes and in agreement with our study (Table 3) , no observed significant association between haplotypes and CAD [14] . In Ben-hadj-Khalifa et al. study, polymorphisms of IL-10(À819) and (À1082) were investigated, and in disagreement with our findings, they did not observe an association between IL-10 polymorphisms and CAD [15] . Lio et al. study indicated that the frequency of IL-10(À1082) G/G genotype is significantly higher in men than in women. Their study also showed that patients with IL-10(À1082) A/A genotype are more susceptible to cardiovascular disease than patients with IL-10(À1082) G/G genotype [16] . Blanco et al. study suggested that allele G of IL-10 (À1082) polymorphism plays no role in transcription of the IL-10 gene. Their findings showed that SNPs has a little genetic effect on the IL-10 plasma level. Transcription of the IL-10 gene depends on the combinations of the different polymorphisms as haplotype [17] . In this study, the results of RT-qPCR showed a decrease in IL-10 gene expression in CAD patients. The decrease in the IL-10 expression may increases susceptibility to CAD (Table 5) . In fact, a T to C substitution and a G to A substitution in IL-10(À819) and (À1082) may activate transcription factor inhibitors and consequently inhibit expression of IL-10 in. These results were partly confirmed by the results presented in Table 4 and indicate these genotypes may be associated with disease severity.
Genetic polymorphisms may have different effects on protein development based on the type of tissue and cell. Therefore, more studies are required to examine the role of IL-10 gene alleles in the development of CAD. IL-10 is just a single player among genes involved in atherosclerosis and thus play a minor role in the complex molecular pathways in CAD. Future studies are expected to examine with larger populations to find better understand the disease.
In conclusion, our results suggest that IL-10 gene promoter polymorphisms may influence both coronary artery disease risks and severity in Iranian patients. Table 2 The genotype and allele distributions of IL-10 polymorphisms in patients with CAD and control group. 
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